Immix Biopharma Inc. announced the presentation of updated data from the ongoing Phase 1b/2 NEXICART-1 (NCT04720313) study of its novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201. The updated dataset consists of 63 multiple myeloma patients (including data on 13 new patients and continued follow-up data on 50 previously enrolled patients), at a poster presentation at the 20th International Myeloma Society Annual Meeting in Athens, Greece on September 27-30, 2023 (72 patient count includes 9 AL Amyloidosis patients which will be announced separately). Updated clinical data in 63 patients from the ongoing NEXICART-1 (NCT04720313) study of NXC-201 for the treatment of relapsed/refractory multiple myeloma are as of the July 17, 2023 data cut-off.  Median follow-up was 11.9 months (range: 0.6-19.0 months).

NXC-201 clinical data showed: 95% overall response rate (36 of 38 patients at the therapeutic dose of 800 million CAR+T cells) in relapsed/refractory multiple myeloma who were not exposed to prior BCMA-targeted therapy, producing a median progression free survival (mPFS) of 12.9 months 90% overall response rate (45 of 50 patients at the therapeutic dose of 800 million CAR+T cells) in relapsed/refractory multiple myeloma (including patients with, and without prior BCMA-targeted therapy) 58% complete response rate (29 out of 50 patients at the therapeutic dose of 800 million CAR+T cells) (including patients with, and without prior BCMA-targeted therapy) Prior NXC-201 dose escalation levels included: 150 x 106 (n=6), 450 x 106 (n=7), and 800 x 106 (n=50) CAR+T cells. The overall response rates for each dose level were: 50%, 86%, and 90%, respectively Favorable NXC-201 safety data support the potential for NXC-201, if ultimately approved, to reduce hospitalization, with an opportunity for use as outpatient CAR-T cell therapy, potentially reducing related hospitalization costs by up to 80% .